Cognetivity Neurosciences' Brain Health Platform Cited as Case Study as Part of Early Dementia Detection Policy Recommendations by Alzheimer's Research UK
Cognetivity Neurosciences' Brain Health Platform Cited as Case Study as Part of Early Dementia Detection Policy Recommendations by Alzheimer's Research UK
Policy paper published by UK's leading dementia research charity emphasizes importance of early detection in dementia diagnosis, citing Cognetivity's CognICA(TM) as an innovative solution for use in primary care
英國領先的痴呆症研究慈善機構發表的一份政策文件強調了早期發現在痴呆症診斷中的重要性，並引用Cognetivity的CognICA(TM)作為初級保健中使用的創新解決方案
Vancouver, British Columbia--(Newsfile Corp. - December 13, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that the company and its flagship tool, CognICA™, have been cited in a newly published policy paper by the UK's leading dementia research charity, Alzheimer's Research UK.
温哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年12月13日)-認知神經科學有限公司。(CSE：CGN)(OTCQB：CGNSF)(FSE：1UB)(“公司”或“認知力”)，一家創建了用於醫療、商業和消費環境的獨特腦健康篩查平臺的科技公司高興地宣佈，該公司及其旗艦工具CognICA™已被英國領先的痴呆症研究慈善機構英國阿爾茨海默氏症研究機構在最新出版的一份政策文件中引用。
Entitled "Improving dementia diagnosis: what could change in primary care?", the policy paper explains the importance of earlier, more accurate diagnosis of dementia and its underlying diseases. The paper also highlights the recent announcement of positive phase III results of the drug, lecanemab by Eisai, and, with this and other disease modifying drugs being developed, the critical role of primary healthcare practitioners in the early detection and diagnosis of the condition. The paper also summarizes the current challenges in the dementia diagnostic pathway and potential solutions, including the deployment of CognICA.
這份題為“改善痴呆症診斷：初級保健中會有什麼變化？”的政策文件解釋了更早、更準確地診斷痴呆症及其潛在疾病的重要性。這篇論文還強調了衞材最近宣佈的藥物lecanemab的第三階段陽性結果，以及隨着這種藥物和其他疾病修改藥物的開發，初級保健醫生在早期發現和診斷這種疾病方面的關鍵作用。文章還總結了痴呆症診斷途徑中目前面臨的挑戰和潛在的解決方案，包括部署CognICA。
In highlighting cognitive testing in primary care as a key area for improvement, the paper takes CognICA as a case study for an innovative tool with the potential to improve the early detection and diagnosis of dementia, leading to better referral rates, more efficient use of healthcare resources and improved patient outcomes.
為了強調初級保健中的認知測試是一個關鍵的改進領域，論文將CognICA作為一種創新工具的案例研究，該工具具有改善痴呆症早期檢測和診斷的潛力，從而導致更好的轉診率、更有效地利用醫療資源和改善患者結果。
CognICA is uniquely suited to this task. It is a short and simple but sensitive test, delivered on a tablet, that can be taken by a patient remotely or in person without the need for administration by a specialist. Owing to its absence of learning effect and capacity to integrate with electronic health record systems, CognICA™ provides an end-to-end cognitive testing solution that can be applied throughout the patient pathway to greatly improve the efficiency of diagnosis and treatment.
CognICA是唯一適合這項任務的公司。這是一種在平板電腦上進行的簡短、簡單但敏感的測試，患者可以遠程或親自進行測試，而不需要專家進行管理。由於缺乏學習效果和與電子健康記錄系統集成的能力，CognICA™提供了可應用於整個患者路徑的端到端認知測試解決方案，大大提高了診斷和治療的效率。
What is more, CognICA has already been deployed as a screening and monitoring tool in primary care in the National Health Service (NHS), as well as internationally. As such, it is already aligned with the recommendations outlined in Alzheimer's Research UK's new policy paper.
更重要的是，CognICA已經被部署為國家衞生服務(NHS)以及國際上初級保健的篩查和監測工具。因此，它已經與英國阿爾茨海默氏症研究中心的新政策文件中概述的建議保持一致。
Dr. Sina Habibi, CEO of Cognetivity, said: "It is an honour for the company and our technology to have been cited by Alzheimer's Research UK, which is a hugely important and influential organization in the dementia disease space."
Cognetivity首席執行官Sina Habibi博士説：“能夠被英國阿爾茨海默氏症研究機構表彰，這是該公司和我們的技術的榮幸，這是痴呆症領域一個非常重要和有影響力的組織。”
"The new policy paper highlights what we at Cognetivity have held as our vision for many years: that early detection and diagnosis of brain health issues, rooted in primary care, are absolutely critical to the efforts of healthcare systems and governments to address the developing dementia crisis. With promising drugs such as Eisai's lecanemab heading towards regulatory approval, it is ever more important that we are able to detect early, and an innovative, forward-thinking approach is key. Happily, CognICA has already been deployed in primary care, both in the UK NHS and internationally, as a powerful screening and monitoring tool; hence, we are well placed to deliver on the vision Alzheimer's Research UK have laid out."
新的政策文件強調了我們Cognetivity多年來的願景：早期發現和診斷植根於初級保健的大腦健康問題，對於醫療保健系統和政府解決不斷髮展的痴呆症危機的努力絕對至關重要。隨着衞材的lecanemab等前景看好的藥物獲得監管部門的批准，我們能夠及早發現變得更加重要，而創新的、前瞻性的方法是關鍵。令人高興的是，CognICA已經在英國NHS和國際上的初級保健中作為一種強大的篩查和監測工具進行了部署；因此，我們處於有利地位，能夠實現英國阿爾茨海默氏症研究中心提出的願景。“
About Cognetivity Neurosciences Ltd.
關於認知性神經科學有限公司
Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.
Cognetivity是一家技術公司，它創建了一個認知測試平臺，用於醫療、商業和消費環境。Cognetivity的ICA使用人工智能和機器學習技術，通過測試大腦大片區域的表現來幫助檢測認知障礙的最早跡象。ICA目前可在美國、英國和歐洲用於臨牀，其他地區的監管批准計劃於2022年進行。
ON BEHALF OF THE BOARD
我代表董事會
"Sina Habibi"
Sina Habibi
《新浪哈比比》
新浪哈比比
Chief Executive Officer and Director
董事首席執行官兼首席執行官
FORWARD-LOOKING STATEMENTS:
前瞻性陳述：
Certain statements included in this news release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "assume" "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.
本新聞稿中包含的某些陳述構成前瞻性信息或陳述(統稱為“前瞻性陳述”)，包括“預期”、“假設”、“相信”、“計劃”、“估計”、“預期”、“打算”、“可能”、“應該”以及與公司或其管理層有關的類似表述。前瞻性陳述不是歷史事實，但反映了對未來結果或事件的當前預期。本新聞稿包含前瞻性陳述。這些前瞻性陳述不是對未來業績的保證，涉及難以預測的風險、不確定因素和假設。此類陳述基於當前預期和各種估計、因素和假設，涉及已知和未知的風險、不確定性和其他因素。這些陳述和信息是基於對目前和未來的業務戰略以及公司未來運營環境的許多假設。除非法律要求，否則公司不承擔更新或修改前瞻性信息以反映新事件或新情況的責任。讀者不應過分依賴該公司的前瞻性陳述。
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
加拿大證券交易所不對本新聞稿的充分性或準確性承擔責任。
For further information: Please visit: or contact: info@cognetivity.com; For media enquiries, please contact: Josh Stanbury, josh@sjspr.co, 416-628-7441
有關更多信息，請訪問：請訪問：或聯繫：info@cognetivity.com；如有媒體查詢，請聯繫：Josh Stanbury，Josh@sjSpr.co，416-628-7441
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。